NCT05715216View on ClinicalTrials.gov

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

February 8, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

Nivolumab

Given by IV (vein)

DRUG

Etigilimab

Given by IV (vein)

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Mereo BioPharma
All Listed Sponsors
collaborator

Mereo BioPharma

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05715216 - EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter